Hikma Pharmaceuticals (LON:HIK) Stock Rating Reaffirmed by Berenberg Bank

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “hold” rating reaffirmed by stock analysts at Berenberg Bank in a report released on Thursday, Marketbeat reports. They presently have a GBX 2,000 ($24.70) price objective on the stock. Berenberg Bank’s target price suggests a potential upside of 4.55% from the stock’s previous close.

Separately, Barclays reaffirmed an “equal weight” rating and issued a GBX 2,000 ($24.70) target price on shares of Hikma Pharmaceuticals in a research note on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of GBX 2,068.75 ($25.55).

Hikma Pharmaceuticals Trading Up 3.2 %

Shares of LON HIK opened at GBX 1,913 ($23.63) on Thursday. Hikma Pharmaceuticals has a 1-year low of GBX 1,711 ($21.13) and a 1-year high of GBX 2,222 ($27.45). The company has a market cap of £4.24 billion, a PE ratio of 2,855.22, a P/E/G ratio of 2.38 and a beta of 0.45. The company has a current ratio of 1.57, a quick ratio of 1.27 and a debt-to-equity ratio of 53.92. The company has a 50-day moving average of GBX 1,887.50 and a two-hundred day moving average of GBX 1,870.12.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.